On Thursday, Precision BioSciences Inc.’s DTIL partner iECURE reported clinical efficacy and safety data in the first patient dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study.ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal-onset Ornithine Transcarbamylase (OTC) deficiency. It utilizes a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables the insertion of a functional copy of the OTC gene.Ornithine transcarbamylase deficiency is a rare genetic condition that ...